Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19
Description
Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by
